Jeffrey Groves, MD
Neurology · Draper, UTNPI 1629196399
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $544,028 of the $627,524 with a category attached, or 86.7%. 50 manufacturers reported payments, led by AbbVie at 32.8% of the total. Among neurology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,843 payments — averaging $340.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$206K
- Teva Pharmaceuticals USA, Inc.$95K
- Biohaven Pharmaceuticals, Inc.$78K
- Lundbeck LLC$61K
- Impel Pharmaceuticals Inc.$35K
- Pfizer$30K
- plus $124K from 44 others
Across 5 payments — averaging $3290.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- Janssen Research & Development, LLC$2K
- Biogen$1K
What the payments were for
- Consulting fees$53,4029%
- Speaking & faculty fees$544,02887%
- Grants$420%
- Travel & lodging$9,2861%
- Food & beverage$20,6173%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$627,524 in reported general payments places this provider in the 95th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 39 | $46,931 |
| Emgality PenGalcanezumab-Gnlm | 48 | $34,482 |
| BotoxOnabotulinumtoxina | 19 | $24,176 |
| AptiomEslicarbazepine Acetate | 16 | $19,574 |
| Glatiramer Acetate | 14 | $19,412 |
| XcopriCenobamate | 17 | $19,212 |
| UbrelvyUbrogepant | 11 | $15,292 |
| QuliptaAtogepant | 11 | $14,038 |
| SavellaMilnacipran Hcl | 20 | $9,752 |
| Memantine Hcl ErMemantine Hcl | 98 | $5,953 |
| Lacosamide | 53 | $5,431 |
| Gabapentin | 107 | $2,392 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 111 | $2,321 |
| Donepezil Hcl | 178 | $2,177 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 38 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta, Savella | $205,662 | $63,25861 claims |
| PfizerNurtec Odt | $29,513 | $46,93139 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $368 | $19,57416 claims |
| SK Life Science, Inc.Xcopri | $1,409 | $19,21217 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $34 | $47022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 neurology providers in Utah.
Other neurology in Draper
- Timothy WestSalt Lake City$856K
- Richard HammondOgden$707K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
- Albert SmithSalt Lake City$122K
- Trevor SquireOgden$112K
- Robert YapundichSt George$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.